Does Ceftaroline Kill Gram-Negative Bacteria?
Yes, ceftaroline has bactericidal activity against gram-negative bacteria, but its spectrum is limited to specific pathogens and does NOT cover extended-spectrum beta-lactamase (ESBL)-producing organisms, carbapenem-resistant bacteria, or Pseudomonas aeruginosa 1.
Gram-Negative Coverage Profile
Organisms Covered (FDA-Approved Indications)
Ceftaroline demonstrates proven clinical efficacy against the following gram-negative bacteria 1:
For Skin Infections:
- Escherichia coli
- Klebsiella pneumoniae
- Klebsiella oxytoca
For Community-Acquired Pneumonia:
- Haemophilus influenzae
- Klebsiella pneumoniae
- Klebsiella oxytoca
- Escherichia coli
Additional In Vitro Activity (Not Clinically Validated)
At least 90% of the following gram-negative bacteria show susceptibility in vitro, though clinical efficacy has not been established in controlled trials 1:
- Citrobacter koseri
- Citrobacter freundii
- Enterobacter cloacae
- Enterobacter aerogenes
- Moraxella catarrhalis
- Morganella morganii
- Proteus mirabilis
- Haemophilus parainfluenzae
Critical Limitations
What Ceftaroline Does NOT Cover
Ceftaroline is NOT active against 1:
- ESBL-producing Enterobacteriaceae (TEM, SHV, or CTX-M families)
- Serine carbapenemases (such as KPC)
- Class B metallo-beta-lactamases
- Class C AmpC cephalosporinases
- Pseudomonas aeruginosa
This is a critical distinction from other fifth-generation cephalosporins like ceftobiprole, which has broader gram-negative coverage including P. aeruginosa 2.
Clinical Context and Positioning
When to Consider Ceftaroline for Gram-Negative Coverage
Ceftaroline's primary clinical value lies in its dual coverage of MRSA and common gram-negative respiratory/skin pathogens 2. The 2021 CAP guidelines position it as a fifth-generation cephalosporin with bactericidal activity against both gram-positive and gram-negative pathogens 2.
Appropriate scenarios:
- Community-acquired pneumonia with suspected MRSA plus typical gram-negative respiratory pathogens (H. influenzae, K. pneumoniae, E. coli)
- Complicated skin infections with mixed gram-positive/gram-negative flora (non-ESBL)
- Patients requiring MRSA coverage who also need activity against susceptible Enterobacteriaceae
When NOT to Use Ceftaroline for Gram-Negative Coverage
Do not rely on ceftaroline when:
- ESBL-producing organisms are suspected or confirmed (use carbapenems instead) 3, 4
- Hospital-acquired infections with risk of multidrug-resistant gram-negatives 3
- Pseudomonas aeruginosa coverage is needed (use ceftazidime-avibactam or ceftolozane-tazobactam) 2
- Carbapenem-resistant Enterobacteriaceae are suspected 4
Comparative Gram-Negative Activity
Research data shows ceftaroline has moderate activity against common ESBL-negative gram-negative bacilli 5, 6:
- 92.2% susceptibility for E. coli
- 94.1% susceptibility for K. pneumoniae
- 97.7% susceptibility for P. mirabilis
- 100% susceptibility for H. influenzae
However, it demonstrates poor activity (MIC₉₀ ≥4 μg/ml) against 6:
- Enterobacter spp.
- Acinetobacter baumannii
- Pseudomonas aeruginosa
- Serratia marcescens
- Stenotrophomonas maltophilia
Key Clinical Pitfall
The most important caveat: While ceftaroline has gram-negative activity, it should never be selected primarily for gram-negative coverage alone. Its unique value is the combination of MRSA activity with gram-negative coverage for susceptible organisms. For serious gram-negative infections, particularly in healthcare settings or with resistance risk factors, broader-spectrum agents (carbapenems, ceftazidime-avibactam, ceftolozane-tazobactam, or piperacillin-tazobactam) are more appropriate 3, 7.